Market Research Report
Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030
|Published by||Roots Analysis||Product code||929147|
|Published||Content info||318 Pages
Delivery time: 1-2 business days
|Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030|
|Published: March 31, 2020||Content info: 318 Pages||
Oligonucleotides have a wide range of applications in medical science. In basic research and diagnostics, these are indispensable to contemporary molecular testing and analytical protocols (such as the polymerase chain reaction (PCR), and DNA sequencing), genomic library construction and artificial gene synthesis. In fact, amid the ongoing coronavirus pandemic, several oligonucleotide manufacturers have started offering critical oligonucleotide chemistries, controls and components for the delivery of COVID-19 detection kits at scale. As therapeutic agents, oligonucleotides are known to be associated with certain unique features, such as high selectivity and potency (similar to biologics), and differentiated pharmacology, which further augment their drug-like properties. Moreover, there are established rational approaches that can be leveraged to design oligonucleotide leads, and the overall cost of such drug development initiatives, compared to conventional small molecule drugs and biologics, is reportedly lower. Vitravene® was the first antisense oligonucleotide-based product in 1998. At present, eight oligonucleotide-based drugs are available in the market, namely (in reverse chronological order of year of approval) GIVLAARI™ (2019), ONPATTRO® (2018), TEGSEDI™ (2018), SPINRAZA® (2016), EXONDYS 51® (2016), DEFITELIO® (2016), KYNAMRO™ (2013), and MACUGEN® (2004). Further, more than 200 unique oligonucleotide-based product candidates are currently being evaluated in various preclinical / clinical phases of development.
According to experts, the use of oligonucleotides as a treatment option is limited due to complexities associated with the synthesis of such compounds. Similar to small molecule drugs, oligonucleotides can be manufactured via chemical synthesis methods, solid phase synthesis being one of the most popular approaches used. However, there are certain technical requirements (chemical modification-related expertise) and complex analytical expertise required for development, synthesis and purification of this class of molecules. As a result, oligonucleotide manufacturing has emerged as a much sought-after capability within the modern biopharmaceutical industry. Presently, a significant proportion of the existing expertise and manufacturing capacity for oligonucleotides belong to contract service providers. In fact, most researchers and many therapy / diagnostic developers have demonstrated preference to outsource oligonucleotide manufacturing operations, instead of building in-house capabilities for the same. Several big pharma companies, despite having proprietary manufacturing capabilities, are known to outsource more than half of their clinical stage oligonucleotide manufacturing operations. In the foreseen future, we anticipate the demand and opportunities for contract manufacturing organizations (CMO) in this domain to rise. Consequently, CMOs need to continue to upgrade their capabilities and infrastructure to keep pace with the evolving product development landscape.
The “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030” report features a detailed study of the current scenario and future potential of the custom synthesis, modification and purification services market for oligonucleotides, which are intended for research, diagnostic, and therapeutic applications.
The following companies and organizations have been mentioned in the report: